Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | AR | P10275 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | MT-CO2 | P00403 | 2/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5740339 | 0.95 | KMT2A (0.72) | KMT2AALDH1A1TDP1MEN1AR | |
| SCHEMBL15919496 | 0.84 | AR (0.52) | KMT2AALDH1A1MEN1ARRAB9A | |
| SCHEMBL11041126 | 0.84 | AR (0.55) | KMT2AALDH1A1MEN1AR | |
| SCHEMBL5740340 | 0.84 | KMT2A (0.91) | KMT2AALDH1A1TDP1MEN1GAA | |
| SCHEMBL13879549 | 0.84 | AR (0.55) | KMT2AALDH1A1MEN1AR | |
| SCHEMBL11167757 | 0.83 | ALDH1A1 (0.62) | KMT2AALDH1A1MEN1ARALOX5 | |
| SCHEMBL15904944 | 0.81 | AR (0.49) | KMT2AALDH1A1TDP1MEN1AR | |
| SCHEMBL13879514 | 0.81 | ALDH1A1 (0.60) | KMT2AALDH1A1ARGAAMAPT | |
| SCHEMBL13879494 | 0.81 | KMT2A (0.72) | KMT2AALDH1A1MEN1ARGAA | |
| SCHEMBL13879492 | 0.79 | AR (0.53) | KMT2AALDH1A1MEN1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| WO-2007047146-A2 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| EP-1244670-B1 | HYDANTOIN DERIVATIVE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USING SAME | MGI GP INC (US) | 2006-03-08 | — | — | EP | disclosed |
| US-6974823-B2 | Hydantoin derivative compounds, pharmaceutical compositions, and methods of using same | GPI NIL HOLDINDGS, INC. (US) | 2005-12-13 | — | — | US | disclosed |
| US-20030203890-A1 | Method for treating nerve injury caused as a result of surgery | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2003-10-30 | — | — | US | disclosed |
| US-20020058685-A1 | Hydantoin derivative compounds, pharmace utical compositions, and methods of using same | GLIAMED, INC. | 2002-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203890-A1 | Method for treating nerve injury caused as a result of surgery | NGF, BDNF, GAP43 | KMT2A 4086/4885ALDH1A1 824/4885TDP1 178/4885 |
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, RTF2 | KMT2A 2463/4885ALDH1A1 1500/4885TDP1 3859/4885 |
| US-20020058685-A1 | Hydantoin derivative compounds, pharmace utical compositions, and methods of using same | HNMT, HAAO, HTR3E | KMT2A 3409/4885ALDH1A1 1066/4885TDP1 1456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.